The global Acute Kidney Injury Treatment market size was estimated to be US$ 1.31 Billion in 2022 and is expected to grow at a CAGR of 7.4% between 2023 to 2032.
Acute kidney injury (AKI) treatment involves managing and treating the underlying cause of the injury and providing supportive care to prevent further damage to the kidneys. The treatment approach depends on the severity of the injury, underlying cause, and the patient's overall health. The primary goals of AKI treatment are to maintain fluid and electrolyte balance, manage complications, and prevent or treat infections. In some cases, hospitalization may be required for close monitoring and management of the condition.
The global acute kidney injury (AKI) treatment market is driven by several factors, including the high incidence of chronic diseases, such as diabetes and hypertension, which are known to cause kidney damage. The growing prevalence of diabetes has led to an increase in AKI incidence, making AKI treatment an important focus area.
Furthermore, there is a growing demand for novel, effective, safe, and affordable AKI treatment options, driving innovation in the AKI treatment landscape, with companies investing heavily in research and development. Positive results from a Phase III clinical trial of Reltecimod, a novel immunomodulatory agent, for the treatment of AKI, demonstrate the potential of such treatments.
Moreover, rising healthcare expenditure globally is driving demand for AKI treatment options, as governments, insurance providers, and patients are willing to invest more in healthcare to improve outcomes and reduce the risk of complications. For instance, in India, the government launched the Ayushman Bharat program in 2018, which aims to provide healthcare coverage to around 500 million people, including those with chronic kidney disease.
These factors are interdependent and have a significant impact on the AKI treatment market. Therefore, it is crucial for companies to continue to focus on developing new and innovative AKI treatments to address the growing demand and unmet medical needs.
Based on treatment type, dialysis is the largest segment in the global acute kidney injury (AKI) treatment market. This is primarily due to the severe nature of AKI cases that require immediate and aggressive treatment, and dialysis is often the most effective and rapid way to remove waste products and excess fluids from the blood when the kidneys are not functioning properly. Dialysis involves the use of a machine to filter the blood, and it can be performed in different ways, including hemodialysis and peritoneal dialysis.
Hemodialysis is the most commonly used method, and it involves the use of an artificial kidney machine to filter the blood outside the body. Peritoneal dialysis, on the other hand, involves the use of the peritoneum, a membrane lining the abdominal cavity, to filter the blood.
While medications are also an important component of AKI treatment, they are often used in conjunction with dialysis or other supportive measures. Medications may be used to manage the underlying cause of AKI, such as antibiotics for infections or diuretics to help remove excess fluid. However, they may not be sufficient to manage the severe complications associated with AKI, such as fluid overload, hyperkalemia, and metabolic acidosis, which require prompt and aggressive treatment with dialysis.
Geographically, the global acute kidney injury treatment market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
Following are some of the major trends in these regions –
North America: North America dominates the global AKI treatment market, owing to the presence of advanced healthcare infrastructure, high healthcare spending, and a growing geriatric population. The United States is the largest market in this region, driven by the high incidence of chronic kidney diseases and rising demand for dialysis.
Europe: Europe is the second-largest market for AKI treatment, driven by the high prevalence of diabetes, hypertension, and cardiovascular diseases, which are major risk factors for AKI. The United Kingdom, Germany, and France are the largest markets in this region, with a high demand for dialysis treatment.
Asia-Pacific: The Asia-Pacific region is expected to witness significant growth in the AKI treatment market due to the large population base, rising healthcare spending, and growing prevalence of chronic diseases. China, India, and Japan are the largest markets in this region, with a high demand for dialysis treatment.
Middle East and Africa: The MEA region is a growing market for AKI treatment, driven by the rising incidence of chronic kidney diseases and the improving healthcare infrastructure in countries such as Saudi Arabia, the United Arab Emirates, and South Africa.
South America: The South American market for AKI treatment is driven by the growing geriatric population and the high prevalence of chronic diseases such as diabetes and hypertension. Brazil and Argentina are the largest markets in this region, with a high demand for dialysis treatment.
Companies operating in the global acute kidney injury (AKI) treatment market are adopting various growth strategies to expand their market presence and gain a competitive edge.
Here are some major growth strategies that these companies are adopting:
Product launches: Companies are launching new products to expand their portfolio of AKI treatment options. For example, in 2020, Baxter International Inc. launched AK 98, a new hemodialysis machine with advanced features for the treatment of AKI.
Strategic collaborations and partnerships: Companies are forming strategic collaborations and partnerships with other companies or academic institutions to develop and commercialize new AKI treatment options. For example, in 2019, Sanofi and Microbiotix, Inc. entered into a collaboration to develop a novel treatment for AKI.
Merger and acquisition: Companies are acquiring other companies to expand their AKI treatment portfolio and gain a larger market share. For example, in 2021, Fresenius Medical Care AG & Co. KGaA acquired NxStage Medical, Inc., a provider of home dialysis products and services.
Geographic expansion: Companies are expanding their geographic presence by entering new markets or expanding their existing presence in emerging markets. For example, in 2019, B. Braun Melsungen AG expanded its business in India by setting up a new production facility for medical devices, including AKI treatment products.
Research and development: Companies are investing heavily in research and development to develop innovative AKI treatment options with better efficacy and safety. For example, in 2020, AstraZeneca Plc announced a collaboration with Kidney Research UK to develop new treatment options for AKI.
AMAG Pharmaceuticals, Inc., AstraZeneca, Baxter International Inc., B. Braun Melsungen AG, BioPorto Diagnostics A/S, Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Terumo Corporation and many more.
By Treatment Type:
By Distribution Channel:
By Region
The acute kidney injury treatment market size was estimated to be US$ 1.31 Billion in 2022.
The acute kidney injury treatment market is expected grow at a CAGR of 7.4% between 2023 to 2032.
The global acute kidney injury (AKI) treatment market is driven by several factors, including the high incidence of chronic diseases, such as diabetes and hypertension, which are known to cause kidney damage.
Dialysis is the largest segment in the global acute kidney injury (AKI) treatment market. This is primarily due to the severe nature of AKI cases that require immediate and aggressive treatment, and dialysis is often the most effective and rapid way to remove waste products and excess fluids from the blood when the kidneys are not functioning properly.
North America dominates the global AKI treatment market, owing to the presence of advanced healthcare infrastructure, high healthcare spending, and a growing geriatric population.
AMAG Pharmaceuticals, Inc., AstraZeneca, Baxter International Inc., B. Braun Melsungen AG, BioPorto Diagnostics A/S, Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Terumo Corporation among others, are the leading players in this market.
The United Kingdom, Germany, and France are the largest markets in this Europe, with a high demand for dialysis treatment.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved